Does PayPal Have a Buyer?

以下是内容的中文翻译： 在本期《Motley Cool 隐藏宝石投资》节目中，主持人 Travis William、Lou Whiteman 和 Rachel Warren 讨论了三个主要的金融故事：PayPal 的潜在收购案、强生公司的最新财报，以及优步在华盛顿特区围绕自动驾驶汽车展开的游说活动。 **PayPal 收购传闻：Stripe 和 Advent International 的报价** 节目首先报道了一则突发新闻：支付巨头 Stripe 和私募股权公司 Advent International 联合提出了一项保密提案，计划收购 PayPal。该报价为每股 60.50 美元，对 PayPal 的估值超过 530 亿美元，较前一天的收盘价溢价 28%。这笔交易得到了 500 亿美元的银行承诺融资支持，提议成立一个五五开的合资伙伴关系，由 Stripe 和 Advent 平等运营 PayPal，保持公司完整而非拆分。 Rachel Warren 指出，PayPal 的估值自 2021 年疫情高峰期的 3600 亿美元以来大幅下跌。此次收购的时机值得关注，因为 PayPal 正在经历内部转型，新任首席执行官正在实施一项旨在节省超过 10 亿美元成本的扭亏为盈计划。对于估值约为 1600 亿美元的非上市公司 Stripe 而言，此次收购可以大幅扩大其业务版图，使其获得数亿消费者账户，并将 PayPal 的消费者品牌与其后端基础设施整合。它还将把 PayPal 的稳定币纳入其生态系统。 Lou Whiteman 对此表示怀疑，指出该报价据报道是在一个月前提出的，泄密很可能来自收购方，旨在迫使 PayPal 做出回应。Lou 承认 PayPal 的内在价值——其强大的品牌和 60 亿美元的自由现金流——但他认为，私募股权部分（Advent）利用这些现金流偿还债务是合理的，这是标准的私募股权策略。然而，他强调了以增长为导向的金融科技公司 Stripe 与一家动机不同的私募股权公司之间，50/50 合资伙伴关系固有的紧张关系。Lou 预测 PayPal 将拒绝该报价，暗示占 75% 股份的机构股东可能会要求每股至少 80 美元的价格。 Travis William 对非上市公司 Stripe 为如此大规模的收购提供资金（可能伴随着巨额债务）表示担忧。考虑到支付基础设施公司盈利能力的不确定性，他质疑这是否是 Stripe 寻求增长的“最后挣扎”。主持人还谈到了 Stripe 这样非上市公司的“价格发现”问题，其私人估值在公开市场可能站不住脚，这使得这笔交易复杂化，并可能演变成“一团糟”。 **强生公司财报：宏观逆风与长期实力** 强生公司（J&J）公布了稳健的财报，营收超过 250 亿美元（增长 7%），调整后每股收益为 2.90 美元（增长 5%），均超出华尔街预期。管理层还将全年销售额指引上调至超过 1010 亿美元，这可能标志着该公司在其近 140 年历史上首次突破 1000 亿美元大关。 尽管业绩积极，强生股价最初仍出现下跌。Rachel 将此归因于其医疗技术部门营收略低于预期，特别是 abiomed 心脏泵的销售额略有下降，以及市场对强生重磅药物 Solara 面临生物仿制药竞争所产生的“短期专利担忧过度关注”。作为一名长期股东，Rachel 将市场反应视为短期噪音，强调强生公司六十年来持续增加股息的历史、多元化的收入来源以及在新重磅药物方面的研发管线，除了 Solara 之外，在 2030 年代初期之前没有重大的专利风险。 Lou Whiteman 呼应了这一观点，指出医疗技术部门的困境很可能是宏观问题，而非强生独有。他指出，Intuitive Surgical 和 HCA 等其他公司也存在类似趋势，这表明医疗保健领域存在周期性，经济困境或医保覆盖问题可能导致择期手术减少。 **优步与自动驾驶汽车：一个“紧张的在位者”的防守** 讨论转向优步在自动驾驶汽车（AV）领域，尤其是在华盛顿特区，扮演的“紧张的在位者”这一意想不到的角色。Lou Whiteman 强调，优步曾是终极颠覆者，现在却在游说反对 Waymo 独立运营。优步倡导的法规将要求机器人出租车在雇佣人类司机的网约车网络上运营，有效地迫使自动驾驶公司与优步等现有平台整合。 Lou 批判性地将优步目前的立场与其颠覆性的起源进行了对比——过去它曾推翻各种法规。他现在认为优步是“汽车时代的马车捍卫者”，利用监管俘获来减缓向完全自动驾驶的过渡，因为他们缺乏专有的无人驾驶解决方案。优步目前的核心“产品”是其客户群，它希望确保这个平台仍然不可或缺。 Rachel Warren 补充说，优步过去激进游说的老套路，曾帮助它赢得了网约车大战，现在却被用来应对另一种威胁。她指出，优步过去曾试图通过规定，强制要求任何无人驾驶公司必须有高比例的人类司机。Travis 提到，优步已在 Lucid 和 Nuro 等各种自动驾驶和电动汽车公司投资了数十亿美元，希望为其网络购买他们的车辆。然而，这些合作尚未有效扩大规模，而 Waymo 已经占据主导地位，每周完成超过 50 万次商业行程。Lou 进一步指出，如果 Lucid 有一个可行的自动驾驶解决方案，优步可能早就收购了他们，这表明他们的自动驾驶技术并没有一些人声称的那么接近。主持人总结道，优步，这个曾经激进的创新者，现在发现自己处于防守姿态，这让投资者感到担忧。

In this episode of Motley Cool Hidden Gems Investing, hosts Travis William, Lou Whiteman, and Rachel Warren discuss three major financial stories: a potential acquisition of PayPal, Johnson & Johnson's latest earnings, and Uber's lobbying efforts concerning autonomous vehicles in Washington D.C. **PayPal Acquisition Rumors: Stripe and Advent International's Bid** The program opens with breaking news regarding a joint confidential proposal from payments giant Stripe and private equity firm Advent International to acquire PayPal. The offer stands at $60.50 per share, valuing PayPal at over $53 billion, representing a 28% premium over its previous day's closing price. This deal, backed by $50 billion in committed bank financing, proposes a 50-50 joint partnership where Stripe and Advent would equally run PayPal, keeping the company intact rather than breaking it up. Rachel Warren points out the significant drop in PayPal's valuation since its pandemic peak of $360 billion in 2021. The timing is notable, as PayPal is undergoing an internal transition with a new CEO implementing a turnaround plan targeting over $1 billion in cost savings. For Stripe, a private company with an estimated $160 billion valuation, this acquisition could massively scale its footprint, granting access to hundreds of millions of consumer accounts and integrating PayPal's consumer brand with Stripe's backend infrastructure. It would also absorb PayPal's stablecoin into its ecosystem. Lou Whiteman expresses skepticism, noting that the offer was reportedly made a month ago and the leak likely came from the acquirers to pressure PayPal into a response. While acknowledging PayPal's inherent value—its strong brand and $6 billion in free cash flow—Lou believes the private equity component (Advent) makes sense for utilizing this cash flow to pay down debt, a standard PE strategy. However, he highlights the inherent tension in a 50-50 partnership between a growth-oriented fintech like Stripe and a private equity firm with different motivations. Lou predicts PayPal will reject the offer, suggesting institutional shareholders, who comprise 75% of ownership, would likely demand a price starting at $80 per share. Travis William raises concerns about Stripe, a private company, financing such a large acquisition, potentially with significant debt. He questions if this is a "last gasp effort" for growth, given the uncertainty about the profitability of payment infrastructure companies. The hosts also touch upon the "price discovery" issue for private companies like Stripe, whose private valuation might not hold up in public markets, making the deal complex and potentially a "convoluted mess." **Johnson & Johnson's Earnings Report: Macro Headwinds vs. Long-Term Strength** Johnson & Johnson (J&J) reported solid earnings, with over $25 billion in revenue (up 7%) and adjusted EPS of $2.90 (up 5%), both beating Wall Street expectations. Management also raised its full-year sales guidance to over $101 billion, marking a potential first for the company to cross the $100 billion milestone in its nearly 140-year history. Despite the positive results, J&J's stock saw an initial dip. Rachel attributes this to a minor revenue miss in their medtech division, particularly with a slight drop in sales for their abiomed heart pumps, and "hyperfixation on short-term patent anxieties" related to their blockbuster drug Solara facing competition from biosimilars. As a long-term shareholder, Rachel views the market reaction as short-term noise, emphasizing J&J's six-decade history of increasing dividends, diversified revenue streams, and a pipeline of new blockbuster drugs with no major patent risks until the early 2030s beyond Solara. Lou Whiteman echoes this sentiment, noting that the medtech division's struggles are likely a macro issue, not specific to J&J. He points to similar trends with other companies like Intuitive Surgical and HCA, suggesting a cyclicality in healthcare where economic woes or coverage issues can lead to a decrease in elective surgeries. **Uber and Autonomous Vehicles: A "Nervous Incumbent" on the Defensive** The discussion shifts to Uber's unexpected role as a "nervous incumbent" in the autonomous vehicle (AV) space, particularly in Washington D.C. Lou Whiteman highlights that Uber, once the ultimate disruptor, is now lobbying against Waymo operating independently. Uber is advocating for regulations that would require robotaxis to operate on ride-hailing networks that also employ human drivers, effectively forcing AV companies to integrate with existing platforms like Uber's. Lou critically contrasts Uber's current stance with its disruptive origins, where it tore down regulations. He now sees them as "defenders of the horse carriage in the age of the automobile," using regulatory capture to slow down the transition to full autonomy because they lack a proprietary driverless solution. Uber's current "product" is its inventory of customers, and it wants to ensure this platform remains indispensable. Rachel Warren adds that Uber's old playbook of aggressive lobbying, which helped it win the ride-sharing war, is now being used to counter a different threat. She points to past attempts by Uber to pass rules that would mandate a high percentage of human drivers for any driverless company. Travis notes that Uber has invested billions in various AV and EV companies like Lucid and Nuro, hoping to buy their vehicles for its network. However, these partnerships are not yet scaling effectively, while Waymo is already dominating, clearing over 500,000 commercial trips weekly. Lou further suggests that if Lucid had a viable autonomous solution, Uber would likely have acquired them already, indicating their AV technology isn't as close as some might claim. The hosts conclude that Uber, once an aggressive innovator, now finds itself in a defensive position, making investors wary.